Perrigo Writes Off $202m Of Value Amid ProAir Recall And Relaunch Uncertainty
Impairment Charge May Be Ten-Times Previous Estimate
Perrigo remains unable to say exactly when it will be able to relaunch its generic to Teva’s ProAir, a position that has left the company with no choice but to impair significantly the value of the asset in the firm’s financial third quarter.
